Statistical Vision has been rebranded as Hahn Stats. Image via Getty Images

Statistical Vision, a Houston-based data and analytics firm, has been scooped up by Austin-based marketing and communications agency Hahn Public for an undisclosed amount.

The deal expands Hahn Public to a 48-person agency with combined annual revenue exceeding $10 million. Statistical Vision has been rebranded as Hahn Stats.

“Our clients come to us drowning in data — sales transactions, marketing information, commodity prices, import and export data, demographics, weather forecasts, etcetera,” Michael Griebe, co-founder and chief statistical officer of what now is Hahn Stats, says in a news release. “We build predictive analytic models to answer specific questions and to point our clients towards revenue growth.”

Griebe and Dirk Van Slyke founded Statistical Vision in 2014. The company's local office is at The Cannon West Houston. Hahn Stats LLC also has an office in Denver.

The data and analytics prowess developed by Statistical Vision will benefit Hahn Public clients like Houston-based ZTERS, Whataburger, the Texas Department of Agriculture, Beef-Loving Texans, H-E-B’s Central Market, Vital Farms, the Propane Education & Research Council, OneGas, GPA Midstream, the East Texas Electric Cooperative, and the Northeast Texas Regional Mobility Authority.

Jeff Hahn, principal of Hahn Public, says the acquisition of Statistical Vision and its data and analytics capabilities will help Hahn Public’s array of food and energy clients, who “continue to face a rapidly changing and uncertain landscape.”

Other businesses under the Hahn umbrella are Apron Food & Beverage Communications, Predictive Media Network, and White Lion Interactive.

Statistical Vision shares key data points it's watching as companies return to work amid the COVID-19 outbreak. Getty Images

Houston data startup analyzes COVID-19 risks as companies return to work

Guest column

In an effort to better help our clients, and frankly all of us, maneuver these uncertain times and to better understand what the upcoming months are likely to bring, we have applied our data science expertise to create a structural model of the spread of COVID-19. The aim of the national model is to determine specifically how mobility and weather impact the local transmission rates while controlling for population density, population immunity rate and the fact that people are taking more precautions.

When I discuss COVID19 with other Houstonians, I'm often asked "We're going back to work — there's traffic! Why haven't cases spiked?"

First, it is worth noting that cases and deaths have increased again in Harris County. But, the question is still valid. Greg Abbott started allowing things to open six weeks ago and we are only starting to see a rise now.

Fortunately, our model (being quantitative and multivariate) can explain why cases may not have 'spiked' the way that was expected. There are four main reasons why cases are only starting to tick up now:

  1. There has not been a 'spike' in people leaving their homes. While Greg Abbott did allow restaurants, movie theaters and malls to begin re-opening on April 30, there was not a sudden spike in people leaving their homes. Indeed, the "people staying home" index, according to Google Mobility Data, peaked on April 1 at 22 percent above normal and has gradually decreased ever since. In Harris County, the extent people are staying at home stands at 14 percent above normal as of May 29 (unfortunately, Google Mobility Data reports 7 to 10 days after the fact.) So, from the peak 'stay at home' measure, we were only a third the way back to normal last week.
  2. Temperatures have increased. Our model indicates that warmer temperatures decrease the transmission rate of COVID19. Our model does not posit a mechanism, but we can rule out both geographic explanations and behavioral explanations, which leaves us with the compelling reason to believe that temperatures matter.
  3. People's behaviors when they do go out have changed. These changes — everything from masks, to skipping hand shakes, to readily available hand sanitizer, to keeping your distance, to staying home when you're feeling sick — have an important and measurable impact on the spread.
  4. Kids are not back in school yet. While our model does not directly measure the impact of kids being in school, the estimate our model produces measuring the importance of staying at home (2.6) is higher than they should be (2, mathematically speaking). We suspect that's because we are missing an important cohort that started staying at home at the same time mobile phone users started staying at home - kids that don't have cell phones. So, while it may seem like we are most of the way back to normal, with regards to going out, being summer time in Houston, kids are not at school, which is likely keeping the rate of spread down.
All of that said, the gradual increase in people leaving their homes has had an impact. And now, cases and deaths are starting to increase. Our model reminds us that there are a variety of factors impacting the transmission rate. Right now, temperatures, people's behaviors and schools being out work in our favor. Come September, two of those three will turn the other way.
------
Michael Griebe is the co-founder and chief statistical officer at Houston-based Statistical Vision. To read more about the company's initiative, click here.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

New Houston biotech co. lands $30M for pulmonary fibrosis drug

drug money

Most of us can claim a scar or two on our bodies. But when scarring develops inside the body, it’s known as a fibrotic disorder. A freshly launched Houston company, Oorja Bio Inc., is working on a treatment that can help to repair cells and reduce the damage wrought by the growth of fibrotic tissue in patients.

Late last month, Oorja Bio hit the scene with a pair of big announcements. Not only has the company raised a $30 million Series A thanks to founding investor California-based Westlake BioPartners, but it has also already paved the way for a Phase 2 study to take place this year.

Oorja Bio received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA), allowing the company to test its treatment in patients with idiopathic pulmonary fibrosis (IPF), a scarring of the lung tissue. IPF affects more than 150,000 adults in the United States and can result in a range of symptoms from shortness of breath to organ failure and death as it progresses.

Oorja Bio’s lead drug candidate, ORJ-001, was shown in a Phase 1 in-human trial to demonstrate “therapeutically relevant exposure and favorable tolerability” in 64 healthy adult volunteers in whom it was administered daily or weekly, according to a news release. Pre-clinical studies of ORJ-001 showed durable target tissue engagement and biomarker activity in bleomycin-induced lung fibrosis.

Administered subcutaneously, ORJ-001 is intended to improve and even restore function in cells that can reduce the signaling that causes IPF. It stops advancement of IPF and also allows for tissue repair. Currently available treatments for the disease can slow the development of IPF down, but do not address the declining lung function that’s inherent in its progression.

“The clinical and preclinical results from our studies to date give us confidence that ORJ-001 represents a novel treatment approach with the potential to repair and reverse fibrosis and modify disease progression in IPF,” Dr. Janethe Pena, CMO of Oorja Bio, said in the release.

“Our team is energized to deliver on our goal of redefining the future of fibrotic diseases, beginning with ORJ-001,” CEO and founder Sujay Kango added. “As we advance ORJ-001 in the clinic, we are embracing the paradigm shift in our biological understanding of IPF pathology that aligns with the central role of the alveolar epithelium. ORJ-001 was designed with this biology in mind and may provide, for the first time, a therapeutic intervention that repairs and reverses fibrosis and promotes disease modification.”

Most patients live only three to five years following their IPF diagnosis. Soon, ORJ-001 and Oorja Bio could give them a fighting chance.

Axiom Space tops $525M in oversubscribed round, announces Swiss subsidiary

funding boost

Axiom Space tacked on an additional $175 million to a previously announced capital raise, bringing the oversubscribed round to a total of more than $525 million.

Axiom shared in February that it had secured $350 million in a financing round led by Type One Ventures and Qatar Investment Authority. In the latest release from the company, Axiom reports that Japan-based MUFG Bank Ltd. joined the round as a new investor, in addition to continued participation from existing backers.

The funding will go toward developing the company's commercial space station, known as Axiom Station, and the production of its Axiom Extravehicular Mobility Unit (AxEMU) under its NASA spacesuit contract.

“Investor interest in this round outpaced what we set out to raise, which speaks to the moment we’re in,” Jonathan Cirtain, CEO and president of Axiom Space, said in the news release. “Our partners see what is possible in low-Earth orbit, and they see who is positioned to lead it.”

Axiom announced last month that it planned to open a Japanese subsidiary July 1. Earlier this week, it also shared plans to establish Axiom Space Switzerland, a wholly owned subsidiary based in Lucerne that is also expected to begin operations this summer.

The Switzerland subsidiary aims to establish Axiom's presence in Europe and help it partner with the European Space Agency and other space organizations and companies on the continent.

“Europe is a founding leader in the creation of the commercial space economy, and Switzerland is uniquely positioned to convene the government agencies, research institutions, and industrial entities that will shape its next decade,” Cirtain added in a separate release. “Axiom Space Switzerland facilitates the scaling of development and deployment of the infrastructure that will succeed the International Space Station.”

Texas cashes in among 10 best U.S. state economies in 2026 report

State Economics

A new study gauging the success or decline in economic performance in every state has revealed Texas' economy remains stable in 2026 after it dropped out of the top five to No. 8 last year.

Texas boasts the No. 8 best state economy in the U.S. this year, according to WalletHub's annual "Best & Worst State Economies" report. The personal finance website's analysts ranked all 50 states and the District of Columbia across 28 relevant metrics to measure each state's economic activity and health status, and its "innovation potential."

Notably, Texas leads the nation for the most exports per capita in the U.S. in a five-way tie with Louisiana, Kentucky, North Dakota, and Indiana. Across the study's three main categories, Texas ranked highly for its economic activity (No. 7) and economic health (No. 11), and the state's "innovation potential" rank is the 24th best in the nation.

This is how WalletHub ranked Texas' economic performance, where No. 1 is considered the best and No. 25 is considered average:
  • No. 6 – Change in non-farm payrolls
  • No. 8 – Change in GDP
  • No. 8 – Startup activity
  • No. 11 – Annual median household income
  • No. 18 – Government surplus/deficit per capita
  • No. 21 – Percentage of jobs in high-tech industries
  • No. 30 – Unemployment rate
WalletHub previously ranked Texas one of the top three states to start a business in 2026, with Houston earning its own entrepreneurial acclaim in separate rankings of the best big cities for new businesses and for starting a career.

"U.S. economic growth depends heavily on the performance of individual states, and some contribute more than others," the report's author wrote. "For example, California, Texas, New York and Florida have economies so large that if they were countries, they would rank in the top 20 in the world."

The five states with the worst state economies in 2026 are Rhode Island (No. 47), Maine (No. 48), Louisana (No. 49), Kentucky (No. 50), and West Virginia (No. 51).

The top 10 best state economies for 2026 are:

  • No. 1 – Massachusetts
  • No. 2 – Washington
  • No. 3 – Utah
  • No. 4 – California
  • No. 5 – Delaware
  • No. 6 – North Carolina
  • No. 7 – New York
  • No. 8 – Texas
  • No. 9 – Colorado
  • No. 10 – Florida

---

This article originally appeared on CultureMap.com.